Clinical, economic, and health-related quality of life impact of intrapartum group B Streptococcus (GBS) tests for prevention of neonatal GBS infection: a systematic literature review.

Sheily Kamra¹, Deepali Moon¹, Natalie Green², Björn Vandewalle³

¹IQVIA, Global Health Economics and Health Technology Assessment, Gurgaon, India.

²IQVIA, Global Health Economics and Health Technology Assessment, London, UK.

³IQVIA, Global Health Economics and Health Technology Assessment, Lisbon, Portugal.

PubMed DOI

Abstract

OBJECTIVE: Group B Streptococcus (GBS) contributes majorly to neonatal morbidity and mortality. Although antenatal culture screening and risk-based intrapartum antibiotic prophylaxis (IAP) reduce neonatal early-onset GBS (EOGBS) compared to no screening, limitations hinder further reduction of EOGBS incidence. Point-of-care polymerase chain reaction (PCR) tests can address these limitations and of…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.